Pasar al contenido principal

Development of personalized cancer therapies based on the inhibition of oncogenic signalling pathways and treatment with cannabinoids

RYC2021-031003-I

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Desarrollar, Atraer y Retener Talento
Subprograma Subprograma Estatal de Incorporación
Convocatoria Ramón y Cajal
Año convocatoria 2021
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDAD COMPLUTENSE DE MADRID

Resultados relacionados

Resultados totales (Incluyendo duplicados): 7
Encontrada(s) 1 página(s)

Docta Complutense
Publicación Artículo científico (JournalArticle)

Non-coding RNAs as mediators of epithelial to mesenchymal transition in metastatic colorectal cancers

  • Nadukkandy, Aisha Shigna
  • Blaize, Britny
  • Kumar, Chethana D.
  • Mori, Giulia
  • Cordani, Marco
  • Dinesh Kumar, Lekha
Colorectal cancer (CRC) remains a leading cause of cancer-related mortality globally, necessitating the development of innovative treatment strategies. Recent research has underscored the significant role of non-coding RNAs (ncRNAs) in CRC pathogenesis, offering new avenues for diagnosis and therapy. In this review, we delve into the intricate roles of various ncRNAs, including microRNAs (miRNAs), long non-coding RNAs (lncRNAs), and circular RNAs (circRNAs), in CRC progression, epithelial-mesenchymal transition (EMT), metastasis, and drug resistance. We highlight the interaction of these ncRNAs with and regulation of key signaling pathways, such as Wnt/β-catenin, Notch, JAK-STAT, EGFR, and TGF-β, and the functional relevance of these interactions in CRC progression. Additionally, the review highlights the emerging applications of nanotechnology in enhancing the delivery and efficacy of ncRNA-based therapeutics, which could address existing challenges related to specificity and side effects. Future research directions, including advanced diagnostic tools, targeted therapeutics, strategies to overcome drug resistance, and the integration of personalized medicine approaches are discussed. Integrating nanotechnology with a deeper understanding of CRC biology offers the potential for more effective, targeted, and personalized strategies, though further research is essential to validate these approaches.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Nanomedicine for autophagy modulation in cancer therapy: a clinical perspective

  • López-Méndez, Tania Belén
  • Sánchez-Álvarez, Miguel
  • Trionfetti, Flavia
  • Pedraz, José Luís
  • Tripodi, Marco
  • Cordani, Marco
  • Strippoli, Raffaele
  • González-Valdivieso, Juan
In recent years, progress in nanotechnology provided new tools to treat cancer more effectively. Advances in biomaterials tailored for drug delivery have the potential to overcome the limited selectivity and side effects frequently associated with traditional therapeutic agents. While autophagy is pivotal in determining cell fate and adaptation to different challenges, and despite the fact that it is frequently dysregulated in cancer, antitumor therapeutic strategies leveraging on or targeting this process are scarce. This is due to many reasons, including the very contextual effects of autophagy in cancer, low bioavailability and non-targeted delivery of existing autophagy modulatory compounds. Conjugating the versatile characteristics of nanoparticles with autophagy modulators may render these drugs safer and more effective for cancer treatment. Here, we review current standing questions on the biology of autophagy in tumor progression, and precursory studies and the state-of-the-art in harnessing nanomaterials science to enhance the specificity and therapeutic potential of autophagy modulators., Work in the laboratories of the authors is funded by grants from the Italian Ministries for Health (Ricerca Corrente) to M.T., from Education, University and Research (MIUR; 000003_17_MAP_STRIP and FISR 2020-Covid FISR2020IP_03366) to R.S; and from the Spanish Ministerio de Ciencia e Innovación (PID2021-128106NA-I00). M.C. is currently a recipient of a Ramón y Cajal tenure track contract from the Spanish Ministry of Science and Innovation (RYC2021-031003-I) and was funded by “Maria Zambrano” contract from Spanish Ministry of Universities and Complutense University of Madrid. M.S-A is recipient of a Ramón y Cajal tenure track contract from the Spanish Ministry of Science and Innovation (RYC2020-029690-I)., Peer reviewed
Docta Complutense
Publicación Artículo científico (JournalArticle)

The role of glycolysis in tumorigenesis: from biological aspects to therapeutic opportunities

  • Cordani, Marco
  • Michetti, Federica
  • Zarrabi, Ali
  • Zarepour, Atefeh
  • Rumio, Cristiano
  • Strippoli, Raffaele
  • Marcucci, Fabrizio
Glycolytic metabolism generates energy and intermediates for biomass production. Tumor-associated glycolysis is upregulated compared to normal tissues in response to tumor cell-autonomous or non-autonomous stimuli. The consequences of this upregulation are twofold. First, the metabolic effects of glycolysis become predominant over those mediated by oxidative metabolism. Second, overexpressed components of the glycolytic pathway (i.e. enzymes or metabolites) acquire new functions unrelated to their metabolic effects and which are referred to as “moonlighting” functions. These functions include induction of mutations and other tumor-initiating events, effects on cancer stem cells, induction of increased expression and/or activity of oncoproteins, epigenetic and transcriptional modifications, bypassing of senescence and induction of proliferation, promotion of DNA damage repair and prevention of DNA damage, antiapoptotic effects, inhibition of drug influx or increase of drug efflux. Upregulated metabolic functions and acquisition of new, non-metabolic functions lead to biological effects that support tumorigenesis: promotion of tumor initiation, stimulation of tumor cell proliferation and primary tumor growth, induction of epithelial-mesenchymal transition, autophagy and metastasis, immunosuppressive effects, induction of drug resistance and effects on tumor accessory cells. These effects have negative consequences on the prognosis of tumor patients. On these grounds, it does not come to surprise that tumor-associated glycolysis has become a target of interest in antitumor drug discovery. So far, however, clinical results with glycolysis inhibitors have fallen short of expectations. In this review we propose approaches that may allow to bypass some of the difficulties that have been encountered so far with the therapeutic use of glycolysis inhibitors.
Docta Complutense
Publicación Artículo científico (JournalArticle)

Small-molecule inhibitors of WNT signalling in cancer therapy and their links to autophagy and apoptosis

  • Menon, Nayana A.
  • Kumar, Chethana D.
  • Ramachandran, Pournami
  • Blaize, Britny
  • Gautam, Mridul
  • Cordani, Marco
Cancer represents an intricate and heterogeneous ailment that evolves from a multitude of epigenetic and genetic variations that disrupt normal cellular function. The WNT/β-catenin pathway is essential in maintaining the balance between cell renewal and differentiation in various tissues. Abnormal activation of this pathway can lead to uncontrolled cell growth and initiate cancer across a variety of tissues such as the colon, skin, liver, and ovary. It enhances characteristics that lead to cancer progression, including angiogenesis, invasion and metastasis. Processes like autophagy and apoptosis which regulate cell death and play a crucial role in maintaining cellular equilibrium are also intimately linked with WNT/ β-catenin pathway. Thus, targeting WNT pathway has become a key strategy in developing antitumor therapies. Employing small molecule inhibitors has emerged as a targeted therapy to improve the clinical outcome compared to conventional cancer treatments. Many strategies using small molecule inhibitors for modulating the WNT/β-catenin pathway, such as hindering WNT ligands' secretion or interaction, disrupting receptor complex, and blocking the nuclear translocation of β-catenin have been investigated. These interventions have shown promise in both preclinical and clinical settings. This review provides a comprehensive understanding of the role of WNT/β-catenin signalling pathway's role in cancer, emphasizing its regulation of autophagy and apoptosis. Our goal is to highlight the potential of specific small molecule inhibitors targeting this pathway, fostering the development of novel, tailored cancer treatments.
Docta Complutense
Publicación Artículo científico (JournalArticle)

Highlighting roles of autophagy in human diseases: a perspective from single-cell RNA sequencing analyses

  • Khalafiyan, Anis
  • Fadaie, Mahmood
  • Fatemeh Khara
  • Zarrabi, Ali
  • Moghadam, Fariborz
  • Khanahmad, Hossein
  • Cordani, Marco
  • Boshtam, Maryam
Autophagy, the lysosome-driven breakdown of intracellular components, is pivotal in regulating eukaryotic cellular processes and maintaining homeostasis, making it physiologically important even under normal conditions. Cellular mechanisms involving autophagy include the response to nutrient deprivation, intracellular quality control, early development, and cell differentiation. Despite its established health significance, the role of autophagy in cancer and other diseases remains complex and not fully understood. A comprehensive understanding of autophagy is crucial to facilitate the development of novel therapies and drugs that can protect and improve human health. High-throughput technologies, such as single-cell RNA sequencing (scRNA-seq), have enabled researchers to study transcriptional landscapes at single-cell resolution, significantly advancing our knowledge of autophagy pathways across diverse physiological and pathological contexts. This review discusses the latest advances in scRNA-seq for autophagy research and highlights its potential in the molecular characterization of various diseases.
Docta Complutense
Publicación Artículo científico (JournalArticle)

MiR-29a-laden extracellular vesicles efficiently induced apoptosis through autophagy blockage in HCC cells

  • Seydi, Homeyra
  • Nouri, Kosar
  • Shokouhian, Bahare
  • Piryaei, Abbas
  • Hassan, Moustapha
  • Cordani, Marco
  • Zarrabi, Ali
  • Shekari, Faezeh
  • Vosough, Massoud
Background. In spite of significant advancements in theraputic modalities for hepatocellular carcinoma (HCC), there is still a high annual mortality rate with a rising incidence. Major challenges in the HCC clinical managment are related to the development of therapy resistance, and evasion of tumor cells apoptosis which leading unsatisfactory outcomes in HCC patients. Previous investigations have shown that autophagy plays crucial role in contributing to drug resistance development in HCC. Although, miR-29a is known to counteract authophagy, increasing evidence revealed a down-regulation of miR-29a in HCC patients which correlates with poor prognosis. Beside, evidences showed that miR-29a serves as a negative regulator of autophagy in other cancers. In the current study, we aim to investigate the impact of miR-29a on the autophagy and apoptosis in HCC cells using extracellular vesicles (EVs) as a natural delivery system given their potential in the miRNA delivery both in vitro and in vivo. Method. Human Wharton’s Jelly mesenchymal stromal cell-derived extracellular vesicles were lately isolated through 20,000 or 110,000 × g centrifugation (EV20K or EV110K, respectively), characterized by western blot (WB), scanning electron microscopy (SEM), and dynamic light scattering (DLS). miR-29a was subsequently loaded into these EVs and its loading efficiency was evaluated via RT-qPCR. Comprehensive in vitro and in vivo assessments were then performed on Huh-7 and HepG2 cell lines. Results. EV20K-miR-29a treatment significantly induces cell apoptosis and reduces both cell proliferation and colony formation in Huh-7 and HepG2 cell lines. In addition, LC3-II/LC3-I ratio was increased while the expression of key autophagy regulators TFEB and ATG9A were downregulated by this treatment. These findings suggest an effective blockade of autophagy by EV20K-miR-29a leading to apoptosis in the HCC cell lines through concomitant targeting of critical mediators within each pathway.
Docta Complutense
Publicación Artículo científico (JournalArticle)

Fisetin attenuates CCl₄-induced liver fibrosis through modulation of TGF-β1/Smad3 and p53/Bax/Bcl-2 signaling pathways

  • Sarabandi, Sahel
  • Cordani, Marco
  • Allameh, Abdolamir
Liver fibrosis arises from a sustained imbalance between oxidative stress, cell death, and matrix deposition. Using the carbon tetrachloride (CCl4) mouse model, we show that the dietary flavonoid fisetin orchestrates a broad hepatoprotective program that blunts this cascade. Male C57BL/6 mice received CCl4 for six weeks, without/with daily fisetin at 50 or 100 mg/kg. Co-treatment with fisetin preserved body weight and lowered the liver index, and markedly attenuated biochemical injury, reducing serum ALT, AST, ALP, GGT, and TBIL while restoring total protein and albumin levels. Fibrogenic burden also decreased, as evidenced by lower circulating PIIINP, reduced hepatic hydroxyproline, as well as reduced expression of COL1A1 and α-SMA. Histology mirrored these improvements: necrosis, inflammation, and collagen accumulation were diminished, with Masson's trichrome and Sirius Red staining revealing dose-dependent normalization of liver architecture. Mechanistically, fisetin restored redox homeostasis (higher TAC, GSH, SOD, CAT, and GPx; lower MDA and TOS) and re-engaged the Nrf2/HO-1 axis at mRNA and protein levels, while simultaneously suppressing profibrotic TGF-β1/Smad3 signaling, including p-Smad3. In parallel, fisetin shifted the apoptotic tone toward cytoprotection, decreasing p53, phospho-p53, and Bax, while increasing Bcl-2, along with decreasing caspase 3/7 activity. These effects were consistently stronger at 100 mg/kg, indicating a dose-response. Together, these data position fisetin as a multifaceted anti-fibrogenic and antioxidant agent that preserves liver structure and function under toxic injury, supporting its candidacy for evidence-based phytotherapeutic strategies against chronic liver disease. According to this data, the Nrf2/HO-1, TGF-β1/Smad3, and p53/Bax/Bcl-2 axes are the main pathways modulated by fisetin intervention.